FAQ: Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights and BIO 2025 Participation

What is Scinai Immunotherapeutics Ltd. announcing?

Scinai Immunotherapeutics Ltd. is announcing CEO Amir Reichman’s participation in the BIO International Convention 2025, showcasing strategic, operational, and financial milestones, including CDMO business growth and nanobody pipeline progress.

How much funding did Scinai Immunotherapeutics Ltd. secure recently?

Scinai Immunotherapeutics Ltd. secured $1.38 million in funding through its Standby Equity Purchase Agreement with Yorkville Advisors, enhancing capital without warrants or additional dilution.

What are Scinai Immunotherapeutics Ltd.’s financial targets?

The company reaffirmed its 2025 CDMO revenue guidance of $2 million and targets achieving breakeven by 2026.

Who is the CEO of Scinai Immunotherapeutics Ltd.?

Amir Reichman is the CEO of Scinai Immunotherapeutics Ltd., who will be participating in the BIO International Convention 2025.

When and where is the BIO International Convention 2025 taking place?

The BIO International Convention 2025 is scheduled for June 16–19 in Boston.

What are the two business units of Scinai Immunotherapeutics Ltd.?

Scinai Immunotherapeutics Ltd. has two business units: one focused on developing inflammation and immunology biological therapeutic products, and a boutique CDMO providing drug development and manufacturing services.

Where can I find more information about Scinai Immunotherapeutics Ltd.?

For more information, visit the company’s website at www.Scinai.com or the latest news and updates at https://ibn.fm/SCNI.

What is the significance of the BIO International Convention participation for Scinai?

Participation in the BIO International Convention 2025 allows Scinai to present its recent milestones and progress to a global audience, enhancing visibility and potential partnerships.

What is the Standby Equity Purchase Agreement?

The Standby Equity Purchase Agreement with Yorkville Advisors is a funding mechanism that provided Scinai with $1.38 million without the need for warrants or causing additional dilution to existing shareholders.